[go: up one dir, main page]

NO20060498L - Metode for a promotere benvekst - Google Patents

Metode for a promotere benvekst

Info

Publication number
NO20060498L
NO20060498L NO20060498A NO20060498A NO20060498L NO 20060498 L NO20060498 L NO 20060498L NO 20060498 A NO20060498 A NO 20060498A NO 20060498 A NO20060498 A NO 20060498A NO 20060498 L NO20060498 L NO 20060498L
Authority
NO
Norway
Prior art keywords
bone growth
promoting bone
calcium
patient
phosphorus
Prior art date
Application number
NO20060498A
Other languages
English (en)
Inventor
Jill Marie Jobbins
Original Assignee
Rhodia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodia filed Critical Rhodia
Publication of NO20060498L publication Critical patent/NO20060498L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Metode for behandling av en pasient for å fremme benvekst, som omfatter: å administrere til pasienten en terapeutisk mengde av et benremodelleringsmiddel som effektivt stimulerer benvekst, og et kosttilskudd som omfatter kalsium og fosfor, i en terapeutisk mengde som effektivt forebygger underskudd av den mengde kalsium eller fosfor som er tilgjengelig for benvekst.
NO20060498A 2003-08-06 2006-01-31 Metode for a promotere benvekst NO20060498L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49288203P 2003-08-06 2003-08-06
PCT/US2004/024792 WO2005016265A2 (en) 2003-08-06 2004-08-02 Method for promoting bone growth

Publications (1)

Publication Number Publication Date
NO20060498L true NO20060498L (no) 2006-02-24

Family

ID=34193155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060498A NO20060498L (no) 2003-08-06 2006-01-31 Metode for a promotere benvekst

Country Status (10)

Country Link
US (1) US20050037089A1 (no)
EP (1) EP1651246A4 (no)
JP (1) JP2007501241A (no)
KR (1) KR20060056975A (no)
AU (1) AU2004264899A1 (no)
CA (1) CA2534577A1 (no)
IL (1) IL173485A0 (no)
MX (1) MXPA06001428A (no)
NO (1) NO20060498L (no)
WO (1) WO2005016265A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
ATE547954T1 (de) * 2008-06-16 2012-03-15 Nutricia Nv Zusammensetzung für die ernährung von säuglingen mit fettgradient
HRP20120929T1 (hr) 2008-09-02 2012-12-31 N.V. Nutricia Prehrambeni pripravci koji sadrže obložene lipidne globule
EP2337569A4 (en) * 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE STOMACH DARM, SKIN AND NOSE MICROBIOTA
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
MX370447B (es) 2013-03-14 2019-12-13 Amip Llc Composición nutricional reservada en fósforo.
WO2015065193A1 (en) 2013-11-01 2015-05-07 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
PL3361885T3 (pl) 2015-10-15 2019-11-29 Nutricia Nv Preparat do początkowego żywienia niemowląt mający specjalną architekturę lipidów do pobudzania zdrowego wzrostu
US9855305B2 (en) 2016-03-29 2018-01-02 Companion Therapeutics Llc Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
DK3874959T3 (da) 2016-12-09 2024-08-05 Nutricia Nv Ernæringsmæssig sammensætning til anvendelse til forbedring af kognitiv ydeevne og/eller forbedring af kognitiv svækkelse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
FI942884A7 (fi) * 1991-12-17 1994-06-16 Procter & Gamble Pharmaceuticals Inc Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja par atyreoideahormonia
CA2159354A1 (en) * 1993-04-02 1994-10-13 R. Curtis Morris Jr. Method and composition for treatment of osteoporosis
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
JP3742523B2 (ja) * 1998-02-27 2006-02-08 雪印乳業株式会社 高分子型カルシウム・ホスホペプチド複合体
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
JP5100923B2 (ja) * 2000-02-16 2012-12-19 雪印メグミルク株式会社 カルシウム・リン酸化澱粉複合体及びその製造方法
US20040137072A1 (en) * 2003-01-13 2004-07-15 Richard Cockrum Method for increasing calcium absorption and bone mineral density through the supplementation of bovine colostrum

Also Published As

Publication number Publication date
WO2005016265A2 (en) 2005-02-24
MXPA06001428A (es) 2006-05-15
EP1651246A2 (en) 2006-05-03
JP2007501241A (ja) 2007-01-25
AU2004264899A1 (en) 2005-02-24
WO2005016265A3 (en) 2005-07-07
EP1651246A4 (en) 2009-06-24
US20050037089A1 (en) 2005-02-17
KR20060056975A (ko) 2006-05-25
IL173485A0 (en) 2006-06-11
CA2534577A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
NO20060498L (no) Metode for a promotere benvekst
ATE312635T1 (de) Ventilanordnung
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
NO20042151L (no) Sammensetning for a forbedre skjelettvekst og opprettholdelse av benhelse
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
TW200612987A (en) Combination treatment for non-hematologic malignancies
BRPI0519178A2 (pt) composiÇço de cuidado oral, e, mÉtodo de prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
EP1677806A4 (en) METHOD FOR THE TREATMENT OF ACUTE AND HYALURONIC ACIDIFICATION CAUSED BY EXCESSIVE INJURY AND STUPIDATION
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
WO2004019873A3 (en) Methods of promoting osteogenesis
NO20060912L (no) Preoperativ behandling for postoperativ smerte
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
BRPI0507302A (pt) método e composições para o tratamento da lipodistrofia
RU2008150987A (ru) Способ лечения переломов длинных трубчатых костей
WO2004024083A3 (en) Methods of bone healing
UA33571A (uk) Спосіб лікування травматичного перелому нижньої щелепи
ATE472323T1 (de) Behandlung von statin-nebenwirkungen mit uridinderivaten
ATE403424T1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
WO2003032895A3 (en) Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer
UA3978U (uk) Спосіб лікування компресійних нейропатій черепно-мозкових нервів у хворих після реконструктивних операцій на прецеребральних артеріях

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application